ADAM-17: a novel therapeutic target for triple negative breast cancer.

Hdl Handle:
http://hdl.handle.net/10147/324259
Title:
ADAM-17: a novel therapeutic target for triple negative breast cancer.
Authors:
McGowan, P M; Mullooly, M; Caiazza, F; Sukor, S; Madden, S F; Maguire, A A; Pierce, A; McDermott, E W; Crown, J; O'Donovan, N; Duffy, M J
Affiliation:
Department of Pathology and Laboratory Medicine, St Vincent's University Hospital, Dublin, Ireland. patricia.mcgowan@ucd.ie
Citation:
McGowan PM et al. ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann. Oncol. 2013, 24 (2):362-9
Journal:
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Issue Date:
Feb-2013
URI:
http://hdl.handle.net/10147/324259
DOI:
10.1093/annonc/mds279
PubMed ID:
22967992
Abstract:
Validated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2 [i.e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors.
Item Type:
Article
Language:
en
Keywords:
BREAST CANCER
Local subject classification:
CELL BIOLOGY
MeSH:
ADAM Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Molecular Targeted Therapy; Phosphorylation; RNA, Messenger; Receptor, Epidermal Growth Factor; Receptor, erbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Transforming Growth Factor alpha
ISSN:
1569-8041

Full metadata record

DC FieldValue Language
dc.contributor.authorMcGowan, P Men_GB
dc.contributor.authorMullooly, Men_GB
dc.contributor.authorCaiazza, Fen_GB
dc.contributor.authorSukor, Sen_GB
dc.contributor.authorMadden, S Fen_GB
dc.contributor.authorMaguire, A Aen_GB
dc.contributor.authorPierce, Aen_GB
dc.contributor.authorMcDermott, E Wen_GB
dc.contributor.authorCrown, Jen_GB
dc.contributor.authorO'Donovan, Nen_GB
dc.contributor.authorDuffy, M Jen_GB
dc.date.accessioned2014-08-05T15:01:03Z-
dc.date.available2014-08-05T15:01:03Z-
dc.date.issued2013-02-
dc.identifier.citationMcGowan PM et al. ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann. Oncol. 2013, 24 (2):362-9en_GB
dc.identifier.issn1569-8041-
dc.identifier.pmid22967992-
dc.identifier.doi10.1093/annonc/mds279-
dc.identifier.urihttp://hdl.handle.net/10147/324259-
dc.description.abstractValidated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2 [i.e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen_GB
dc.subjectBREAST CANCERen_GB
dc.subject.meshADAM Proteins-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCell Line, Tumor-
dc.subject.meshCell Proliferation-
dc.subject.meshCell Survival-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMolecular Targeted Therapy-
dc.subject.meshPhosphorylation-
dc.subject.meshRNA, Messenger-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.subject.meshReceptor, erbB-2-
dc.subject.meshReceptors, Estrogen-
dc.subject.meshReceptors, Progesterone-
dc.subject.meshSignal Transduction-
dc.subject.meshTransforming Growth Factor alpha-
dc.subject.otherCELL BIOLOGYen_GB
dc.titleADAM-17: a novel therapeutic target for triple negative breast cancer.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Pathology and Laboratory Medicine, St Vincent's University Hospital, Dublin, Ireland. patricia.mcgowan@ucd.ieen_GB
dc.identifier.journalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMOen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.